{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:56:57Z","timestamp":1785772617834,"version":"3.56.0"},"reference-count":38,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"2","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adult T-cell leukemia\/lymphoma (ATL) is a rare and aggressive type of peripheral T-cell malignancy caused by the human T-lymphotropic virus type 1 (HTLV-1). Approximately 5 to 10 million people are infected with HTLV-1 worldwide, with high prevalence in Japan. This observational study analyzed patient characteristics, treatment patterns, healthcare resource utilization (HRU), and costs of ATL in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of ATL patients from the Medical Data Vision database, Sept.\u00a01, 2012\u2013Aug.\u00a031, 2022, was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1572 ATL patients, 384 received systemic therapy. The mean age at diagnosis was 66.4 years, with 63.7% being \u226565 years; 55.2% patients were females. Excluding cancer, 61% of patients had a Charlson Comorbidity Index score of 0. The most frequently observed comorbidities were congestive heart failure (15.8%), diabetes (14.8%), and peptic ulcer disease (14.6%). Among the treated patients, 37.5% received 1 line of therapy, 26% received 2 lines of therapy, and 36.5% received \u22653 lines. Mogamulizumab was most frequently utilized (60.4%), as monotherapy or in combination regimens. The most common combination regimen in all lines of therapy were cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), utilized in 46.6% of patients. Additionally, use of combinations such as VCAP-AMP-VECP, which include vincristine, cyclophosphamide, doxorubicin, and prednisone; adriamycin, manimustine, and prednisone; and vindesine, etoposide, carboplatin, and prednisone, was observed in 33.3% of patients. Initial treatment was discontinued in 74.7% patients; only 3.4% received stem cell transplants. Most (96%) patients were hospitalized, 29.7% had emergency room visits, and 79.4% averaged 1.8 outpatient visits monthly. The mean all-cause healthcare cost per patient per month was $29\u2009538 (\u00a54\u2009647\u2009300), mainly due to outpatient visits and hospitalizations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusion\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although real-world studies based on MDV database have certain limitations, the findings of this study provide deeper understanding of the real-world patient characteristics, treatment patterns, HRU, and costs of ATL patients in Japan. The results indicate that patients often encounter high treatment costs and frequent hospitalizations, demonstrating the necessity for advanced regimens and highlighting the unmet need for more effective therapies in ATL patients that may reduce HRU and economic burden in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.162558","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:25:05Z","timestamp":1785770705000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":0,"title":["Adult T-cell Leukemia\/Lymphoma in Japan: Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs"],"prefix":"10.36469","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-9738","authenticated-orcid":true,"given":"Charles","family":"Dharmani","sequence":"first","affiliation":[{"name":"Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5928-224X","authenticated-orcid":false,"given":"Zahid","family":"Islam","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-9936","authenticated-orcid":false,"given":"Pingping","family":"Qu","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1671-0881","authenticated-orcid":false,"given":"Zoe","family":"Jiang","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3536-4033","authenticated-orcid":false,"given":"Jingjian","family":"Wang","sequence":"additional","affiliation":[{"name":"DeltaMed Solutions, Inc., Somerset, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0702-8778","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"DeltaMed Solutions, Inc., Somerset, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3578-4007","authenticated-orcid":false,"given":"Yijing","family":"Tao","sequence":"additional","affiliation":[{"name":"DeltaMed Solutions, Inc., Somerset, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7311-3020","authenticated-orcid":false,"given":"Lin","family":"Song","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co. Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"D. M. Parkin","year":"2006","journal-title":"Int J Cancer"},{"issue":"6","key":"ref2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"C. de Martel","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"ref3","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"M. Plummer","year":"2016","journal-title":"Lancet Glob Health"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fmicb.2012.00322","article-title":"Adult T-cell leukemia: a review of epidemiological evidence","volume":"3","author":"M. Iwanaga","year":"2012","journal-title":"Front Microbiol"},{"issue":"10","key":"ref5","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1111\/cas.15097","article-title":"Epidemiology of adult T-cell leukemia-lymphoma in Japan: an updated analysis, 2012-2013","volume":"112","author":"S. Ito","year":"2021","journal-title":"Cancer Sci"},{"issue":"6","key":"ref6","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.3109\/10428194.2014.964700","article-title":"The incidence of adult T-cell leukemia\/lymphoma among human T-lymphotropic virus type 1 carriers in Japan","volume":"56","author":"M. Satake","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/v14040791","article-title":"Nationwide hospital-based survey of adult T-cell leukemia\/lymphoma in Japan","volume":"14","author":"T. Kato","year":"2022","journal-title":"Viruses"},{"issue":"6","key":"ref8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1182\/bloodadvances.2017011106","article-title":"Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States","volume":"2","author":"L. Malpica","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"ref9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1182\/blood.2019004045","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"137","author":"L. B. Cook","year":"2021","journal-title":"Blood"},{"issue":"14","key":"ref10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","article-title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","volume":"132","author":"U. A. Shah","year":"2018","journal-title":"Blood"},{"issue":"12","key":"ref11","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"B. J. Poiesz","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"32","key":"ref12","doi-asserted-by":"publisher","first-page":"51981","DOI":"10.18632\/oncotarget.10223","article-title":"Adult T-cell leukemia\/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy","volume":"7","author":"M. Zell","year":"2016","journal-title":"Oncotarget"},{"issue":"39","key":"ref13","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1038\/sj.onc.1208979","article-title":"Natural history of adult T-cell leukemia\/lymphoma and approaches to therapy","volume":"24","author":"G. P. Taylor","year":"2005","journal-title":"Oncogene"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.2741\/1442","article-title":"Adult T cell leukemia lymphoma","volume":"9","author":"L. Ratner","year":"2004","journal-title":"Front Biosci"},{"issue":"12","key":"ref15","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/cas.13398","article-title":"Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: a nationwide survey","volume":"108","author":"K. Nosaka","year":"2017","journal-title":"Cancer Sci"},{"issue":"1","key":"ref16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12185-024-03864-3","article-title":"Safety and effectiveness of lenalidomide in Japanese patients with relapsed\/refractory ATLL: post-marketing surveillance","volume":"121","author":"T. Miyazaki","year":"2025","journal-title":"Int J Hematol"},{"issue":"2","key":"ref17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","article-title":"Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center","volume":"9","author":"T. Laurent","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"ref18","article-title":"MDV EBM insight"},{"issue":"6","key":"ref19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/10245332.1998.11746417","article-title":"HTLV-1 and adult T-Cell leukemia\/lymphoma: a review","volume":"3","author":"F. Ravandi-Kashani","year":"1998","journal-title":"Hematology"},{"issue":"5","key":"ref20","doi-asserted-by":"publisher","first-page":"100646","DOI":"10.1016\/j.mayocpiqo.2025.100646","article-title":"Comorbidity Disease Pattern in Japanese Elderly Population: A Network-Based Analysis","volume":"9","author":"S. Nojiri","year":"2025","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"2","key":"ref21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12185-025-04011-2","article-title":"JSH practical guidelines for hematological malignancies, 2023: II. lymphoma 9\u2014adult T-cell leukemia\u2013lymphoma (ATL)","volume":"122","author":"K. Nosaka","year":"2025","journal-title":"Int J Hematol"},{"issue":"6","key":"ref22","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","article-title":"Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease","volume":"79","author":"M. Yoshida","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"34","key":"ref23","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"K. Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"110616","DOI":"10.1016\/j.clim.2025.110616","article-title":"Prognostic value of lymphocyte-to-monocyte ratio in relapsed\/refractory adult T-cell leukemia\/lymphoma patients receiving mogamulizumab","volume":"282","author":"Y. Shimazu","year":"2026","journal-title":"Clin Immunol"},{"issue":"4","key":"ref25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/cas.12617","article-title":"Recent advances in the treatment of adult T-cell leukemia-lymphomas","volume":"106","author":"A. Utsunomiya","year":"2015","journal-title":"Cancer Sci"},{"issue":"11","key":"ref26","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1038\/bcj.2013.57","article-title":"Association between decreasing trend in the mortality of adult T-cell leukemia\/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT)","volume":"3","author":"D. Chihara","year":"2013","journal-title":"Blood Cancer J"},{"issue":"16","key":"ref27","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-022-01800-5","article-title":"Valemetostat tosilate: first approval","volume":"82","author":"S. J. Keam","year":"2022","journal-title":"Drugs"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"932914","DOI":"10.3389\/fphar.2022.932914","article-title":"Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment","volume":"13","author":"Y. Sun","journal-title":"Front Pharmacol"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"101431","DOI":"10.1016\/j.clinre.2020.03.029","article-title":"Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: a multicenter prospective AGEO study","volume":"45","author":"L. J. Palmieri","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"15","key":"ref30","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/fon-2023-0615","article-title":"Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma","volume":"20","author":"C. Dharmani","year":"2024","journal-title":"Future Oncol"},{"issue":"1","key":"ref31","doi-asserted-by":"publisher","DOI":"10.36469\/001c.161191","article-title":"Peripheral T-cell lymphoma in Japan: real-world patient characteristics, treatment patterns, healthcare resource utilization, and costs","volume":"13","author":"C. Dharmani","year":"2026","journal-title":"JHEOR"},{"issue":"3","key":"ref32","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"15","author":"A. Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"107654","DOI":"10.1016\/j.leukres.2025.107654","article-title":"Trends of changes in human T-cell leukemia virus type 1 epidemiology in Japan and globally","volume":"150","author":"N. Yoshida","year":"2025","journal-title":"Leuk Res"},{"issue":"3","key":"ref34","doi-asserted-by":"publisher","first-page":"e28606","DOI":"10.1002\/jmv.28606","article-title":"Lower prevalence of anti-HTLV-1 as expected by previous models among first-time blood donors in Japan","volume":"95","author":"M. Satake","year":"2023","journal-title":"J Med Virol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fmicb.2020.01124","article-title":"Epidemiology of HTLV-1 infection and ATL in Japan: an update","volume":"11","author":"M. Iwanaga","year":"2020","journal-title":"Front Microbiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.coviro.2016.08.009","article-title":"Human T-cell leukemia virus-associated malignancy","volume":"20","author":"A. R. Panfil","year":"2016","journal-title":"Curr Opin Virol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.21037\/aol-21-6","article-title":"Adult T-cell leukemia\/lymphoma\u2014pathobiology and implications for modern clinical management","volume":"5","author":"L. Cook","year":"2021","journal-title":"Ann Lymphoma"},{"issue":"2","key":"ref38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ijc.2910450206","article-title":"The 4th nation-wide study of adult T-cell leukemia\/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group","volume":"45","author":"K. Tajima","year":"1990","journal-title":"Int J Cancer"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/162558-adult-t-cell-leukemia-lymphoma-in-japan-real-world-treatment-patterns-healthcare-resource-utilization-and-costs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:25:06Z","timestamp":1785770706000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/162558-adult-t-cell-leukemia-lymphoma-in-japan-real-world-treatment-patterns-healthcare-resource-utilization-and-costs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.162558","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}